The influence of genetic variation on late toxicities in childhood cancer survivors: A review

The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained by treatment and baseline patient characteristics. Inter-individual variability in the association between treatment exposure and risk of late toxicity suggests that genetic variation possibly modifies this association. We reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment related to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impairment.

Source: Critical Reviews in Oncology Hematology - April 12, 2018 Category: Cancer & Oncology Authors: E. Clemens, A.L.F. van der Kooi, L. Broer, E. van Dulmen-den Broeder, H. Visscher, L. Kremer, W. Tissing, J. Loonen, C.M. Ronckers, S.M.F. Pluijm, S.J.C.M.M. Neggers, O. Zolk, T. Langer, A. am Zehnhoff-Dinnesen, C.L. Wilson, M.M. Hudson, B. Carleton, J.S. Source Type: research